A vaccine to prevent Alzheimer's before symptoms start just got a major regulatory boost. The FDA has granted Fast Track designation to AV-1959R, an investigational vaccine targeting amyloid-beta buildup in cognitively healthy adults. Developed by Nuravax, the vaccine showed a solid safety profile in a phase 1 trial, with a larger phase 2 trial set to kick off in early 2027.
A vaccine to prevent Alzheimer's before symptoms start just got a major regulatory boost.
The FDA has granted Fast Track designation to AV-1959R, an investigational vaccine developed by Nuravax aimed at preventing Alzheimer's disease in cognitively unimpaired adults who already show biomarker evidence of amyloid buildup in the brain. The vaccine is designed to trigger antibody responses against pathological forms of amyloid-beta — the protein that accumulates silently in the brain for up to two decades before any symptoms appear.
A phase 1 trial confirmed AV-1959R was safe, well tolerated, and capable of producing antibodies that selectively target the most harmful amyloid forms (protofibrils and fibrils). A phase 2 trial (AREVIA) is expected to launch in early 2027.
By the Numbers:
Why it matters: Most Alzheimer's treatments target the disease after damage is already underway. A preventive vaccine that intervenes during the silent, pre-symptomatic window could be a game-changer for millions at risk.
